4.6 Review

Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy

期刊

CANCERS
卷 7, 期 4, 页码 1959-1982

出版社

MDPI
DOI: 10.3390/cancers7040870

关键词

BRAF; RAF; MEK; immunotherapy; HDAC; histones; methyltransferase; bromodomain; BET; chromatin modifiers; resistance; PRC2; EZH2; PD-L1; PD-1

类别

资金

  1. Australian National Health and Medical Research Council (NHMRC) [633004]

向作者/读者索取更多资源

The treatment of melanoma has been revolutionized by new therapies targeting MAPK signaling or the immune system. Unfortunately these therapies are hindered by either primary resistance or the development of acquired resistance. Resistance mechanisms involving somatic mutations in genes associated with resistance have been identified in some cases of melanoma, however, the cause of resistance remains largely unexplained in other cases. The importance of epigenetic factors targeting histones and histone modifiers in driving the behavior of melanoma is only starting to be unraveled and provides significant opportunity to combat the problems of therapy resistance. There is also an increasing ability to target these epigenetic changes with new drugs that inhibit these modifications to either prevent or overcome resistance to both MAPK inhibitors and immunotherapy. This review focuses on changes in histones, histone reader proteins and histone positioning, which can mediate resistance to new therapeutics and that can be targeted for future therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据